Stockscreener 앱 받기
19.32
3.43%
0.64
시간 외 거래:
19.32
전일 마감가:
$18.68
열려 있는:
$18.68
하루 거래량:
3.14M
Relative Volume:
0.95
시가총액:
$2.76B
수익:
$62.38M
순이익/손실:
$-101.59M
주가수익비율:
-22.35
EPS:
-0.8644
순현금흐름:
$-139.93M
1주 성능:
+12.65%
1개월 성능:
+56.44%
6개월 성능:
+154.21%
1년 성능:
+1,020%
1일 변동 폭
$18.46
$19.55
1주일 범위
$16.77
$19.55
52주 변동 폭
$1.03
$19.55
Tango Therapeutics Inc Stock (TNGX) Company Profile
명칭
Tango Therapeutics Inc
전화
(857) 320-4900
주소
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
19.32 | 2.67B | 62.38M | -101.59M | -139.93M | -0.8644 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-23 | 개시 | Mizuho | Outperform |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-17 | 개시 | Jefferies | Buy |
| 2024-04-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-02-12 | 개시 | Piper Sandler | Overweight |
| 2023-12-08 | 개시 | B. Riley Securities | Buy |
| 2022-10-20 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | 개시 | SVB Leerink | Outperform |
모두보기
Tango Therapeutics Inc 주식(TNGX)의 최신 뉴스
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology - GlobeNewswire Inc.
It Takes Two To TangoClinical Progress, Solid Balance Sheet Driving Momentum In TNGX - RTTNews
Can Tango Therapeutics Inc be recession proofMarket Trend Review & High Return Stock Watch Alerts - baoquankhu1.vn
Guidance Update: Can Tango Therapeutics Inc sustain earnings growth2026 Institutional Moves & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Guidance Update: Is Tango Therapeutics Inc undervalued by DCF analysis2026 Earnings Impact & Verified Technical Signals - baoquankhu1.vn
Tango Therapeutics stock hits 52-week high at $17.64 By Investing.com - Investing.com South Africa
Does Tango Therapeutics (TNGX) Trial Pact and ESOP Shelf Hint at a Pivotal Strategic Turn? - simplywall.st
Tango Therapeutics (NASDAQ:TNGX) Hits New 12-Month HighShould You Buy? - MarketBeat
Why Tango Therapeutics Stock Is Breaking Out Now - TipRanks
Tango Therapeutics stock hits 52-week high at $17.64 - Investing.com
Farallon Capital Management LLC Buys 1,600,000 Shares of Tango Therapeutics, Inc. $TNGX - MarketBeat
Assessing Tango Therapeutics (TNGX) Valuation After Vopimetostat Progress And New Erasca Collaboration - simplywall.st
Tango Therapeutics, Inc. $TNGX Shares Sold by Trv Gp Iv LLC - MarketBeat
Avoro Capital Advisors LLC Takes $4.58 Million Position in Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics (TNGX) Soars 52% on Buy Reco - MSN
Tango Therapeutics’ (TNGX) Sees Cautious Analyst Optimism Following Earnings - Insider Monkey
11 Best Day Trading Stocks to Buy Now - Insider Monkey
Tango Therapeutics Inc (TNGX) Stock News & Articles - 24/7 Wall St.
Mizuho Forecasts Strong Price Appreciation for Tango Therapeutics (NASDAQ:TNGX) Stock - MarketBeat
Stifel raises Tango Therapeutics stock price target on PRMT5 data - Investing.com Nigeria
Wedbush Reaffirms Outperform Rating for Tango Therapeutics (TNGX) - Bitget
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
Adam Crystal Sells 20,251 Shares of Tango Therapeutics (NASDAQ:TNGX) Stock - MarketBeat
Tango Therapeutics Insider Sold Shares Worth $303,765, According to a Recent SEC Filing - marketscreener.com
Insider sale: Tango Therapeutics (TNGX) R&D president sells shares - Stock Titan
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention - 24/7 Wall St.
Is Erasca (ERAS) Quietly Reframing Its RAS Strategy With Tango’s Dual-Target Trial Collaboration? - Yahoo Finance
Tango Therapeutics (NASDAQ:TNGX) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat
Stifel raises Tango Therapeutics stock price target on PRMT5 data By Investing.com - Investing.com Australia
Tango Therapeutics (TNGX) Valuation Check After Strong Share Price Momentum And High P/S Multiple - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), McKesson (MCK) and Cybin (HELP) - The Globe and Mail
Tango Therapeutics (NASDAQ:TNGX) Lowered to Hold Rating by Wall Street Zen - MarketBeat
Blue Owl Capital Holdings LP Sells 695,000 Shares of Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS - The Globe and Mail
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Tango Therapeutics (TNGX) Q4 Revenue Collapse To US$0 Reinforces Bearish Volatility Narrative - simplywall.st
New hire gets options on 367,500 Tango Therapeutics shares - Stock Titan
Tango Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Tango Therapeutics: I'm Not Buying Into Latest Rally, Despite PRMT5 Promise (NASDAQ:TNGX) - Seeking Alpha
Tango Therapeutics (NASDAQ:TNGX) Issues Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Tango Therapeutics Stock Jumps 36% to a New High. Here’s What’s Driving the Move - TIKR.com
Wedbush Issues Positive Forecast for Tango Therapeutics (NASDAQ:TNGX) Stock Price - MarketBeat
Tango Therapeutics Stock Surges 36% on Strong Q4 Results, Pipeline Momentum and Cash Runway Extension - International Business Times Australia
Tango Therapeutics (NASDAQ:TNGX) Given New $20.00 Price Target at Guggenheim - MarketBeat
Tango Therapeutics (TNGX) Q4 Loss Narrows to $0.29/Share vs $0.33 Estimate; Shares Surge 23% - AlphaStreet
Tango Therapeutics (NASDAQ:TNGX) Price Target Raised to $27.00 at HC Wainwright - MarketBeat
4 Analysts Have This To Say About Tango Therapeutics - Benzinga
Rafferty Asset Management LLC Purchases New Position in Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights - Sahm
Tango Therapeutics Inc (TNGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):